Branch Tx develops orally available dual‑kinase inhibitors that simultaneously block WNT/β‑catenin and PI3Kα pathways, targeting cancer stem cells to prevent tumor recurrence and treatment resistance. The drugs are designed with a precision biomarker strategy and are ready for combination therapies, aiming to deliver safer, longer‑lasting responses in solid tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors often develop resistance to standard therapies due to cancer stem cells that rely on convergent WNT/β‑catenin and PI3Kα signaling pathways, leading to recurrence and limited durable responses.
Solution
Branch Therapeutics creates orally administered dual‑kinase inhibitors that simultaneously block both WNT/β‑catenin and PI3Kα pathways, directly targeting the signaling networks that sustain cancer stem cells and drive adaptive resistance. The molecules are designed for high specificity and favorable pharmacokinetics to enable chronic dosing. A precision biomarker program identifies patients whose tumors exhibit activation of these pathways, ensuring the drugs are used in the most responsive populations. The agents are engineered to be compatible with existing and emerging combination regimens, aiming to provide safer and longer‑lasting therapeutic outcomes for patients with solid tumors who have failed prior treatments.
Target Audience
Primary customers are pharmaceutical partners and oncology research programs developing therapies for solid‑tumor indications, as well as clinical investigators seeking targeted agents for patients with treatment‑resistant disease.
Features
- Dual inhibition of WNT/β‑catenin and PI3Kα signaling with a single oral small‑molecule agent
- Rational drug design focused on high selectivity and favorable oral bioavailability
- Integrated precision biomarker platform to select tumors with pathway activation
- Combination‑ready formulation compatible with standard chemotherapies, targeted agents, and immunotherapies
- Preclinical data demonstrating suppression of cancer stem cell self‑renewal and reduced tumor recurrence